Kohjin Bio Co., Ltd. (TYO:177A)
845.00
-2.00 (-0.24%)
Aug 27, 2026, 3:30 PM JST
Kohjin Bio Revenue
Kohjin Bio had revenue of 974.00M JPY in the quarter ending June 30, 2026, a decrease of -20.10%. This brings the company's revenue in the last twelve months to 4.69B, down -9.45% year-over-year. In the fiscal year ending March 31, 2026, Kohjin Bio had annual revenue of 4.94B, down -5.13%.
Revenue (ttm)
4.69B
Revenue Growth
-9.45%
P/S Ratio
0.92
Revenue / Employee
26.67M
Employees
176
Market Cap
4.33B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.94B | -267.00M | -5.13% |
| Mar 31, 2025 | 5.21B | 436.00M | 9.14% |
| Mar 31, 2024 | 4.77B | 28.00M | 0.59% |
| Mar 31, 2023 | 4.74B | 795.00M | 20.14% |
| Mar 31, 2022 | 3.95B | 809.83M | 25.81% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Soiken Holdings | 3.87B |
| Human Metabolome Technologies | 1.42B |
| Kringle Pharma | 342.21M |
| Cyfuse Biomedical K.K. | 305.00M |
| D. Western Therapeutics Institute | 247.00M |
| Ribomic | 7.50M |